ID   NOS-1 [Human osteosarcoma]
AC   CVCL_1610
SY   NOS1
DR   CLO; CLO_0050812
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioSample; SAMN03472210
DR   Cell_Model_Passport; SIDM00242
DR   ChEMBL-Cells; CHEMBL3308836
DR   ChEMBL-Targets; CHEMBL2366141
DR   Cosmic; 925345
DR   Cosmic-CLP; 925345
DR   DepMap; ACH-002067
DR   EGA; EGAS00001000978
DR   GDSC; 925345
DR   GEO; GSM1670284
DR   LINCS_LDP; LCL-1432
DR   PharmacoDB; NOS1_1166_2019
DR   RCB; RCB1032
DR   Wikidata; Q54930911
RX   PubMed=1449054;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Characteristics: Established from a xenograft established in a nude mice.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0%; Native American=0.97%; East Asian, North=79.98%; East Asian, South=18.61%; South Asian=0.44%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Derived from sampling site: Bone; left proximal tibia.
ST   Source(s): Cosmic-CLP; RCB
ST   Amelogenin: X
ST   CSF1PO: 9,13
ST   D13S317: 9,12
ST   D16S539: 10,12,13
ST   D5S818: 10,12
ST   D7S820: 8,12,13 (RCB)
ST   D7S820: 8,13 (Cosmic-CLP)
ST   TH01: 6
ST   TPOX: 11
ST   vWA: 14,16
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   16Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 16-12-21; Version: 27
//
RX   PubMed=1449054; DOI=10.1111/j.1440-1827.1992.tb03110.x;
RA   Hotta T., Motoyama T., Watanabe H.;
RT   "Three human osteosarcoma cell lines exhibiting different phenotypic
RT   expressions.";
RL   Acta Pathol. Jpn. 42:595-603(1992).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//